DegludecPlus insulin degludec/insulin aspart regulatory update

Novo Nordisk submitted an NDA in Japan for DegludecPlus insulin degludec/insulin aspart to treat Type I and II diabetes. The product is also under review in Europe and the U.S., where it has a July 29...